Skip to main content
Premium Trial:

Request an Annual Quote

Accuri Raises $5M in Venture Funds for Cytometer Launch

NEW YORK (GenomeWeb News) - Accuri Cytometers has netted $5 million in Series B financing from Baird Venture Partners and Arboretum Ventures, the company said today.
 
Accuri said it will use the money to fund further testing and to propel the full commercial launch of its C6 flow cytometer system.
 
The C6 system is targeted toward labs that require flow cytometry hardware but lack the funds to buy a high-priced instrument. Accuri plans to market the product for under $30,000.
 
The company said the system is currently in beta testing.
 
CEO Jennifer Baird said the funding will "carry Accuri through broader beta testing and position us for full commercial launch next year."
 
Accuri also said that BVP's Pete Shagory and Arboretum's Tim Peterson have joined its board of directors.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.